| Brown University, PhD | |
| Physics |
Dale Pfost joined Advent in 2010. He has more than 25 years of experience as a life science entrepreneur and executive, with expertise in high technology research tools, genomics, diagnostics and therapeutics.
Dale’s first company, founded while he was in graduate school, was acquired by SmithKline Beckman. He was founding CEO and Chairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine that Dale and his team built through strategic acquisitions and took public in 2000 (NASDAQ: ORCH). Dale then became founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company that was acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale readied the company for a successful acquisition by a European biotechnology firm. Earlier in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE).
